In the Q1 of this year, our revenue increased significantly to $59,000,000 compared to $18,400,000 for the same period last year. Most of our revenue in the quarter or $58,600,000 Was derived from 3 non recurring sources, dollars 41,200,000 in deferred revenue recognition Related to our former collaboration with Janssen, dollars 11,100,000 associated with Janssen wind down activities And $6,200,000 of R and D expense reimbursement under our ongoing collaboration with Ono related to the completion of preclinical activities for FT825. Research and development expenses for the quarter Decreased by $6,500,000 to $65,600,000 The decrease in our R and D expenses Was attributable primarily to the termination of the Janssen collaboration, a decrease in share based compensation expense and from lower demand for R and D Supplies and Materials. General and administrative expenses For the Q1 increased by $1,200,000 to $21,900,000 The increase in our G and A expenses was attributable primarily to an increase in legal related fees. Total operating expenses for the Q1 were $87,600,000 which includes $12,900,000 of severance and other employee termination related expenses as well as $11,000,000 Note that in connection with the development of our off the shelf iPSC derived CAR T cell product candidate FT819, we previously achieved the clinical milestone Set forth in our amended license agreement with Memorial Sloan Kettering Cancer Center, which triggered a first milestone payment to MFK in 2021.